Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.

Progression-free survival (PFS) was longer with a combination of lenvatinib (Lenvima, Eisai) and everolimus (Afinitor, Novartis) than with everolimus alone as second-line treatment for metastatic renal cell cancer (RCC), according to the results of a phase 2 trial. Dr Robert Motzer, a professor of medicine at Weill Cornell Medical College in New York, New York, presented results from the study at the recent meeting of the American Society of Clinical Oncology.1 The addition of lenvatinib to everolimus increased median PFS from 5.5 months to 14.6 months. In addition, there was a trend toward increased overall survival (OS) in the combination group vs everolimus.